During SME Instrument Phase I, a complete feasibility study of the project has been conducted. Regarding the AVR module, although it has been successfully validated and it has a great potential to detect some important chronical diseases, more scientific evidence is needed yet, before its introduction into the market. The RD module has also been validated, and our market research has confirmed the great interest of Health Authorities and RD Screening Program Managers in introducing software for automated detection of RD in current screening programs. RETINAL solution also offers a low-cost fundus camera, specifically designed for capturing retinal images, which has been tecnically validated. We have deeply analyze current approaches to RD screening in the reference markets, and the characteristics of the available fundus cameras and automated software for the detection of DR worldwide, as well as the regulations that affect the commercialization of RETINAL solution. There is a clear opportunity for RETINAL introduction into the market and the feasibility study has confirmed the viability of this new business of UES.